Suppr超能文献

溃疡性结肠炎中的益生菌和益生元

Probiotics and prebiotics in ulcerative colitis.

作者信息

Derikx Lauranne A A P, Dieleman Levinus A, Hoentjen Frank

机构信息

Inflammatory Bowel Disease Centre, Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, The Netherlands.

Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada.

出版信息

Best Pract Res Clin Gastroenterol. 2016 Feb;30(1):55-71. doi: 10.1016/j.bpg.2016.02.005. Epub 2016 Feb 9.

Abstract

The intestinal microbiota is one of the key players in the etiology of ulcerative colitis. Manipulation of this microflora with probiotics and prebiotics is an attractive strategy in the management of ulcerative colitis. Several intervention studies for both the induction and maintenance of remission in ulcerative colitis patients have been performed. Most of these studies evaluated VSL#3 or E. Coli Nissle 1917 and in general there is evidence for efficacy of these agents for induction and maintenance of remission. However, studies are frequently underpowered, lack a control group, and are very heterogeneous investigating different probiotic strains in different study populations. The absence of well-powered robust randomized placebo-controlled trials impedes the widespread use of probiotics and prebiotics in ulcerative colitis. However, given the promising results that are currently available, probiotics and prebiotics may find their way to the treatment algorithm for ulcerative colitis in the near future.

摘要

肠道微生物群是溃疡性结肠炎病因中的关键因素之一。使用益生菌和益生元对这种微生物群进行调控是治疗溃疡性结肠炎的一种有吸引力的策略。已经开展了多项针对溃疡性结肠炎患者诱导缓解和维持缓解的干预研究。这些研究大多评估了VSL#3或大肠杆菌Nissle 1917,总体而言,有证据表明这些制剂在诱导缓解和维持缓解方面具有疗效。然而,这些研究往往样本量不足,缺乏对照组,而且在不同研究人群中研究不同益生菌菌株时差异很大。缺乏有力的、严格的随机安慰剂对照试验阻碍了益生菌和益生元在溃疡性结肠炎中的广泛应用。然而,鉴于目前已有的令人鼓舞的结果,益生菌和益生元可能在不久的将来进入溃疡性结肠炎的治疗方案中。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验